Page last updated: 2024-12-07

carboxyamido-triazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carboxyamido-triazole: structure given in first source; coccidiostat; U.S. patent No. 4,590,201 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108144
CHEMBL ID95431
SCHEMBL ID18866
MeSH IDM0171917

Synonyms (70)

Synonym
AC-6332
CHEMBL95431
1h-1,3-triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-
mls003373924 ,
nsc-609974
NSC609974 ,
99519-84-3
l 651582
CAI ,
5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide
1h-1,2,3-triazole-4-carboxamide, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-
carboxyamidotriazole
NCI60_004782
rfe-007
l-651582
5-amino-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1h-1,2,3-triazole-4-carboxamide
NCGC00014926
NCI609974
4-cai
nsc 609974
5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1h-1,2,3-triazole-4-carboxamide
l651582
carboxyamido-triazole
1h-1,2,3-triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-
NCISTRUC1_001699
NCISTRUC2_001836
NCGC00098026-01
sr-01000902267
SR-01000902267-2
methyl4-amino-5-nitro-2-pyridinecarboxylate
smr002048715
CCG-37684
NCGC00014926-02
6st3zf52wb ,
ccris 9404
unii-6st3zf52wb
NCGC00014926-03
bdbm97191
5-azanyl-1-[[3,5-bis(chloranyl)-4-(4-chlorophenyl)carbonyl-phenyl]methyl]-1,2,3-triazole-4-carboxamide
cid_108144
5-amino-1-[[3,5-dichloro-4-[(4-chlorophenyl)-oxomethyl]phenyl]methyl]-4-triazolecarboxamide
5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl)benzyl]triazole-4-carboxamide
MLS006010700
5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-4,5-dihydrotriazole-4-carboxamide
5-amino-1(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide
5-amino-1-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide
WNRZHQBJSXRYJK-UHFFFAOYSA-N
5-amino-l-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide
5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide
5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)1,2,3-triazole-4-carboxamide
5-amino-1-(4-[4-chlorobenzoyl]-3,5-dichlorobenzyl)-1,2,3-triazole-4-carboxamide
5-amino-1-(4-(4-chlorobenzoyl)-3,5-dichlorobenzyl)- 1,2,3-triazole-4-carboxamide
SCHEMBL18866
l-651,582
5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1h-1,2,3-triazole-4-carboxamide
AKOS024457417
DTXSID40244108
carboxyamidotriazole, >=98% (hplc)
DB11960
FT-0740142
Q5038072
merck l651582
HY-16126
l-651582;cai
carboxiamidotriazol
SB17291
CS-0006152
MS-27475
EN300-7392978
5-amino-1-{[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl}-1h-1,2,3-triazole-4-carboxamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The low toxicity of CAI in vivo combined with the significant difference between toxicity for human and mouse progenitors in vitro suggests a relatively low adverse potential to the bone marrow for this new signal transduction inhibitory agent."( In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells.
Cole, K; Kohn, EC; Sandeen, MA; Volpe, DA, 1995
)
0.29
"0 introduced the collection of attribution of adverse events (AEs) to study drug."( Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
"We conducted a phase I trial of carboxyamidotriazole (CAI, NSC 609974), designed to determine the maximum-tolerated dose (MTD), toxicity profile, and pharmacokinetic characteristics of CAI gelatin capsule (gelcap) formulation administered daily as a single oral dose."( Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Alberti, D; Arzoomanian, RZ; Berlin, J; Cleary, J; Feierabend, C; Hutson, P; Rago, RP; Tutsch, KD; Wilding, G, 1997
)
0.3
" Pharmacokinetic sampling was performed on days 1 and 29 and trough plasma CAI levels were assessed weekly."( Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Alberti, D; Arzoomanian, RZ; Berlin, J; Cleary, J; Feierabend, C; Hutson, P; Rago, RP; Tutsch, KD; Wilding, G, 1997
)
0.3
" A phase I dose escalation trial with pharmacokinetic analysis has been performed."( Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Bauer, KS; Davis, PA; Figg, WD; Kohn, EC; Liotta, LA; Reed, E; Sarosy, GA; Soltis, MJ; Thompkins, A, 1997
)
0.3
" Plasma samples were taken to characterize the pharmacokinetic parameters of this formulation of CAI."( Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Bauer, KS; Davis, PA; Figg, WD; Kohn, EC; Liotta, LA; Reed, E; Sarosy, GA; Soltis, MJ; Thompkins, A, 1997
)
0.3
" Pharmacokinetic analysis demonstrated reduced bioavailability (58% reduction) compared with the PEG-400 liquid formulation previously reported."( Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Bauer, KS; Davis, PA; Figg, WD; Kohn, EC; Liotta, LA; Reed, E; Sarosy, GA; Soltis, MJ; Thompkins, A, 1997
)
0.3
" The objective of this study was to characterize the pharmacokinetic profile from the first Phase I clinical trial of CAI for the single test dose and multiple daily dosing schedule."( Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Boudoulas, S; Cole, KA; Davis, PA; Figg, WD; Goldspiel, B; Jacob, J; Piscitelli, SC; Reed, E; Soltis, MJ; Steinberg, SM, 1995
)
0.56
" A series of pharmacokinetic (PK) models were fit to the concentration-time data."( Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Bauer, KS; Davis, P; Figg, WD; Kohler, D; Kohn, EC; Lush, RM; Reed, E; Steinberg, SM, 1998
)
0.55
"We conducted a Phase II clinical trial of the antiproliferative, antimetastatic, and antiangiogenic agent carboxyamido-triazole (CAI), using pharmacokinetic assessment to guide drug dosing."( A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Bauer, KS; Dyer, V; Figg, WD; Hamilton, JM; Jones, EC; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM, 1999
)
0.77
" Pharmacokinetic analysis revealed that PAX caused an acute increase in circulating CAI concentrations in a dose-dependent fashion."( A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A, 2001
)
0.64
" Toxicity and pharmacokinetic assessments were performed weekly."( Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
Alberti, D; Arzoomanian, RZ; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Marnocha, R; Pluda, J; Tutsch, KD; Wilding, G, 2002
)
0.31
" In most patients administration of ketoconazole produced an increase in CAI AUC and Cmax with a decrease in CAI clearance."( A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
DeMario, M; Desai, AA; Fleming, GF; Innocenti, F; Janisch, L; Ramirez, J; Ratain, MJ; Shepard, D, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic analysis demonstrated reduced bioavailability (58% reduction) compared with the PEG-400 liquid formulation previously reported."( Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Bauer, KS; Davis, PA; Figg, WD; Kohn, EC; Liotta, LA; Reed, E; Sarosy, GA; Soltis, MJ; Thompkins, A, 1997
)
0.3
" This model estimates independent absorption rate constants and relative fraction absorbed for each condition."( Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Bauer, KS; Davis, P; Figg, WD; Kohler, D; Kohn, EC; Lush, RM; Reed, E; Steinberg, SM, 1998
)
0.55
" Bioavailability of the micronized formulation relative to a gelatin capsule (gelcap) formulation was assessed."( Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
Alberti, D; Arzoomanian, RZ; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Marnocha, R; Pluda, J; Tutsch, KD; Wilding, G, 2002
)
0.31
"Carboxyamido-triazole (CAI) is an orally bioavailable calcium influx and signal transduction inhibitor that has been shown to be anti-invasive, anti-angiogenic and anti-metastatic in different human tumors including transitional cell carcinoma."( Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
Demant, AW; Kohn, EC; Müller, SC; Perabo, FG; Schmidt, DH; Sitia, M; Wardelmann, E; Wirger, A,
)
3.02
" In this study, we show that carboxyamidotriazole (CAI), an orally bioavailable calcium influx and signal transduction inhibitor, is equally effective in inhibiting the proliferation and bcr-abl dependent- and independent-signaling pathways in imatinib-resistant CML cells."( Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Alessandro, R; Colomba, P; Corrado, C; De Leo, G; Flugy, AM; Fontana, S; Giordano, M; Kohn, EC; Santoro, A, 2008
)
0.35
" Carboxyamidotriazole-orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown to possess antileukaemic activities."( Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The objective of this study was to characterize the pharmacokinetic profile from the first Phase I clinical trial of CAI for the single test dose and multiple daily dosing schedule."( Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Boudoulas, S; Cole, KA; Davis, PA; Figg, WD; Goldspiel, B; Jacob, J; Piscitelli, SC; Reed, E; Soltis, MJ; Steinberg, SM, 1995
)
0.56
" Following the initial dosage adjustment, 93% (14 of 15) of patients were within the predicted range."( A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Bauer, KS; Dyer, V; Figg, WD; Hamilton, JM; Jones, EC; Linehan, WM; Pluda, JM; Premkumar, A; Reed, E; Steinberg, SM, 1999
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency5.01190.01846.806014.1254AID624417
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency10.48550.000811.382244.6684AID686978; AID686979
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.16230.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.69330.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency21.71680.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency37.90830.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency26.83700.00108.379861.1304AID1645840
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
IDH1Homo sapiens (human)Potency9.20000.005210.865235.4813AID686970
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.50120.00636.904339.8107AID883
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency5.01193.548119.542744.6684AID743266
survival motor neuron protein isoform dHomo sapiens (human)Potency4.46680.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.16230.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.58490.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency37.90830.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency0.50120.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency37.68583.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency37.90830.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
galanin receptor type 3Homo sapiens (human)IC50 (µMol)1.86960.00661.54317.3650AID687013; AID743095
transactivating tegument protein VP16 [Human herpesvirus 1]Human alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)85.40300.94604.70169.4870AID720547
COUP transcription factor 2 isoform aHomo sapiens (human)IC50 (µMol)9.20600.02233.71509.2060AID720548
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID51228The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51405The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51238The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51263The compound was tested for anti-coccidial activity in chicken against Eimeria necatrix (Aquet) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51408The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51418The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51401The compound was tested for anti-coccidial activity in chicken against Eimeria necatrix (Aquet) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51412Anticoccidial activity in chicken against E. tenella1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51227The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51229The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID1807722Selectivity index, ratio of antiinflammatory activity in mouse BMDM cells assessed as inhibition of TNF-alpha production to antiinflammatory activity in mouse BMDM cells assessed as inhibition of IL1-beta production2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel triazole compounds as selective IL-1β releasement inhibitors.
AID51235The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID754491Inhibition of human Rce1p using quenched fluorogenic substrate by fluorescence assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID51407The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51236The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51252The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51253The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51419The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 60 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51409The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51264The compound was tested for anti-coccidial activity in chicken against Eimeria necatrix (Aquet) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51092Anticoccidial activity in chicken against Eimeria acervulina.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51249The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51406The compound was tested for anti-coccidial activity in chicken against Eimeria praecox (DP-785) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51239The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51237The compound was tested for anti-coccidial activity in chicken against Eimeria brunetti (FS-103) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51250The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51226The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51417The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 30 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51416The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51262The compound was tested for anti-coccidial activity in chicken against Eimeria necatrix (Aquet) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID1807721Antiinflammatory activity in mouse BMDM cells assessed as inhibition of TNF-alpha production relative to control2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel triazole compounds as selective IL-1β releasement inhibitors.
AID51402The compound was tested for anti-coccidial activity in chicken against Eimeria necatrix (Aquet) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID754490Inhibition of yeast Rce1p using yeast a-factor mating pheromone substrate2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID51225The compound was tested for anti-coccidial activity in chicken against Eimeria acervulina (DP-761) measured at dose 15 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51251The compound was tested for anti-coccidial activity in chicken against Eimeria maxima (DP-776) measured at dose 45 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID51420The compound was tested for anti-coccidial activity in chicken against Eimeria tenella (DP-761) measured at dose 7.5 (ppm in diet)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Benzylated 1,2,3-triazoles as anticoccidiostats.
AID1807720Antiinflammatory activity in mouse BMDM cells assessed as inhibition of IL1-beta production relative to control2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel triazole compounds as selective IL-1β releasement inhibitors.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's35 (34.65)18.2507
2000's39 (38.61)29.6817
2010's20 (19.80)24.3611
2020's7 (6.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.63 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (14.29%)5.53%
Reviews6 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other84 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT00003869]Phase 3186 participants (Actual)Interventional1999-04-30Completed
A Phase II Randomized Discontinuation Trial Of Carboxyaminoimidazole (CAI, NSC 609974) In Metastatic Renal Carcinoma [NCT00006486]Phase 2335 participants (Actual)Interventional2000-10-31Completed
A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure [NCT01954030]Phase 117 participants (Actual)Interventional2013-10-31Terminated(stopped due to Study terminated early due to funding reasons prior to completing Phase 1)
A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma [NCT01989052]Phase 19 participants (Actual)Interventional2014-05-31Terminated(stopped due to This study was terminated early due to funding issues prior to completion of phase I)
A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [NCT00019461]Phase 20 participants Interventional1998-04-30Completed
A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA [NCT00019019]Phase 170 participants (Anticipated)Interventional1994-10-31Completed
A Phase I Investigation of Carboxyamido-triazole (CAI) Modulated by Ketoconozole In Patients With Advanced Malignancies [NCT00003249]Phase 130 participants (Actual)Interventional1998-05-31Completed
Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme [NCT00004146]Phase 255 participants (Actual)Interventional2000-03-31Completed
Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy [NCT00005045]Phase 20 participants Interventional2000-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00003869 (5) [back to overview]Clinically Significant (10-point) Decrease in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Quality of Life (QOL)Assessment From Baseline to Week 8
NCT00003869 (5) [back to overview]Clinically Significant (10-point) Decrease in UNISCALE Quality of Life (QOL)Assessment From Baseline to Week 8
NCT00003869 (5) [back to overview]Overall Survival (OS)
NCT00003869 (5) [back to overview]Participants With Severe Non-hematologic Adverse Events
NCT00003869 (5) [back to overview]Time to Disease Progression (TTP)
NCT00004146 (3) [back to overview]Correlation Between PK CAI and Toxicity in This pt Population
NCT00004146 (3) [back to overview]Overall Survival Rate
NCT00004146 (3) [back to overview]Toxicity of CAI When Combined With RT

Clinically Significant (10-point) Decrease in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Quality of Life (QOL)Assessment From Baseline to Week 8

The FACT-L is a 36-item Likert instrument that combines frequency of symptomatic/QOL problems with perceived relative importance of each issue. It includes 4 constructs of well being: physical, social/family, emotional and functional, and a fifth construct, additional concerns, dealing solely with tumor related symptoms. Questionnaires were completed at baseline and 8 weeks. Questions within each construct were summated to obtain a construct score. A higher score relates to higher quality of life. A 10 point or greater decline (from baseline to week 8) was considered clinically significant. (NCT00003869)
Timeframe: Baseline to week 8

Interventionparticipants (Number)
Carboxyamidotriazole27
Placebo33

[back to top]

Clinically Significant (10-point) Decrease in UNISCALE Quality of Life (QOL)Assessment From Baseline to Week 8

The UNISCALE was used to assess QOL. UNISCALE is a single item global measure of QOL. Participant were to complete the questionnaire at baseline and every 8 weeks, prior to assessment by the treating physician. A high score indicates a higher quality of life while a low score represents a lower quality of life. A 10 point or greater decline (from baseline to week 8) in UNISCALE QOL score was considered clinically significant. (NCT00003869)
Timeframe: Baseline to week 8

Interventionparticipants (Number)
Carboxyamidotriazole28
Placebo32

[back to top]

Overall Survival (OS)

OS was defined as the time from randomization to death of any cause. Participants who did not die or were lost to follow-up were censored at the time of last evaluation/follow-up date. Patients were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method. (NCT00003869)
Timeframe: up to 5 years

InterventionMonths (Median)
Carboxyamidotriazole11.4
Placebo10.5

[back to top]

Participants With Severe Non-hematologic Adverse Events

Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC version 2.0) (NCT00003869)
Timeframe: every cycle during treatment

InterventionParticipants (Number)
Carboxyamidotriazole38
Placebo30

[back to top]

Time to Disease Progression (TTP)

"TTP is defined as the time from randomization to first documented disease progression(PD). Patients who were lost to follow-up were censored at the time of last evaluation. For patients who died without clear documentation, PD was assumed at the midpoint of the time interval between last evaluation and death. Median TTP was estimated using the Kaplan Meier method.~Measurable PD: ≥25% increase in the sum of the products of two greatest perpendicular diameters of all indicator lesions or appearance of new lesion(s). Evaluable PD: definite increase in tumor size or appearance of new lesion(s)" (NCT00003869)
Timeframe: up to 5 years

InterventionMonths (Median)
Carboxyamidotriazole2.8
Placebo2.4

[back to top]

Correlation Between PK CAI and Toxicity in This pt Population

PK paramenters including steady state CAI concentrations with toxicity/or drug activity (NCT00004146)
Timeframe: during treatment

Interventionug/ml (Mean)
CAI With RT + Enzyme Inducing Anticonvulsants1.3
CAI With RT Without Enzyme Inducing Anticonvulsants4.06

[back to top]

Overall Survival Rate

estimated period of time event assessed 30 months. event assessed from time of histological diagnosis to death (NCT00004146)
Timeframe: approximately 30 months

Interventionmonths (Median)
CAI With RT - Arm 110.3

[back to top]

Toxicity of CAI When Combined With RT

patients who experienced a grade 3 or higher event considered at least possibly related to CAI (NCT00004146)
Timeframe: pts were reviewed for toxicity while on treatement - median time of 2 months

Interventionparticipants (Number)
CAI With RT - Arm 116

[back to top]